NO20076468L - Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger - Google Patents
Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetningerInfo
- Publication number
- NO20076468L NO20076468L NO20076468A NO20076468A NO20076468L NO 20076468 L NO20076468 L NO 20076468L NO 20076468 A NO20076468 A NO 20076468A NO 20076468 A NO20076468 A NO 20076468A NO 20076468 L NO20076468 L NO 20076468L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- methods
- preparing
- cox
- inhibitor
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000007972 injectable composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000002193 Pain Diseases 0.000 abstract 3
- 239000003112 inhibitor Substances 0.000 abstract 2
- 238000007918 intramuscular administration Methods 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- 208000025978 Athletic injury Diseases 0.000 abstract 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010037660 Pyrexia Diseases 0.000 abstract 1
- 208000008765 Sciatica Diseases 0.000 abstract 1
- 201000002661 Spondylitis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002980 postoperative effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Det beskrives ny og meget stabile farmasøytiske sammensetninger omfattende i det minste en syklooksygenase II enzym (COX-II) inhibitor eller ikke-steroidale antiinflammatoriske medikament (NSAID) eller COX/LOX inhibitor, eller dets tautomere former, analoger, isomerer, polymorger, solvater, prodrug eller salter derav som aktive ingredienser egnet for parenteral administrering, fortrinnsvis via intramuskulær (IM) eller intravenøs (IV) rute; fremgangsmåter for å fremstille slike sammensetninger og terapeutiske metoder for anvendelse av slike sammensetninger tilveiebringes. De analgetiske og antiinflammatoriske injiserbare sammensetninger i følge oppfinnelsen er svært nyttige i pattedyr, spesielt i mennesker, for behandling av akutte smertefulle tilstander så som en eller flere av postoperativt traume, smerte assosiert med cancer, idrettskader, migrene hodepine, nevrologisk smerte og smerte assosiert med isjias og spondylitt og lignende, og/eller kroniske smertefulle tilstander, og/eller tilhørende forstyrrelser så som inflammasjon, feber, allergi eller lignende.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1357DE2005 | 2005-05-27 | ||
| PCT/IN2006/000177 WO2006126214A2 (en) | 2005-05-27 | 2006-05-25 | Injectable compositions and process for preparation of such compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076468L true NO20076468L (no) | 2008-02-27 |
Family
ID=36917368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076468A NO20076468L (no) | 2005-05-27 | 2007-12-14 | Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1895983A2 (no) |
| JP (1) | JP2008542260A (no) |
| KR (1) | KR20080016689A (no) |
| CN (1) | CN101217939A (no) |
| AU (1) | AU2006250765A1 (no) |
| BR (1) | BRPI0611170A2 (no) |
| CA (1) | CA2609242A1 (no) |
| CR (1) | CR9616A (no) |
| EA (1) | EA200702646A1 (no) |
| MX (1) | MX2007014862A (no) |
| NO (1) | NO20076468L (no) |
| RS (1) | RS20070461A (no) |
| TN (1) | TNSN07482A1 (no) |
| WO (1) | WO2006126214A2 (no) |
| ZA (1) | ZA200711068B (no) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2698721A1 (en) | 2007-09-07 | 2009-03-12 | United Therapeutics Corporation | Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same |
| AU2010224063B2 (en) | 2009-03-12 | 2015-04-16 | Cumberland Pharmaceuticals Inc | Administration of intravenous ibuprofen |
| US8871810B2 (en) | 2009-07-15 | 2014-10-28 | Cumberland Pharmaceuticals Inc. | Treating critically ill patients with intravenous ibuprofen |
| CN102335114B (zh) * | 2010-07-23 | 2015-07-15 | 重庆医药工业研究院有限责任公司 | 一种稳定的布洛芬精氨酸注射剂及其制备方法 |
| CN102370615B (zh) * | 2010-08-19 | 2013-09-04 | 四川科伦药物研究有限公司 | 一种布洛芬注射制剂及其制备方法 |
| US9447065B2 (en) | 2011-10-18 | 2016-09-20 | Raqualia Pharma Inc. | Pharmaceutical composition |
| CN102512383A (zh) * | 2011-12-25 | 2012-06-27 | 天津市嵩锐医药科技有限公司 | 供注射用的帕瑞昔布钠药物组合物 |
| US9072710B2 (en) | 2012-03-16 | 2015-07-07 | Cumberland Pharmaceuticals Inc. | Injectable ibuprofen formulation |
| CN103372216B (zh) * | 2012-04-26 | 2015-05-06 | 北京京卫燕康药物研究所有限公司 | 一种含有塞来昔布的固体药物组合物 |
| US20140187635A1 (en) * | 2012-12-28 | 2014-07-03 | Themis Medicare Limited | Diclofenac compositions |
| TWI646091B (zh) | 2012-12-28 | 2019-01-01 | 日商衛斯克慧特股份有限公司 | 鹽類及晶形 |
| US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
| CN103263385B (zh) * | 2013-05-17 | 2016-04-27 | 江苏正大清江制药有限公司 | 一种塞来昔布长效纳米注射剂及其制备方法 |
| TN2017000232A1 (en) * | 2014-12-20 | 2018-10-19 | Troikaa Pharmaceuticals Ltd | Injectable formulations of paracetamol |
| WO2016170401A1 (en) * | 2015-04-20 | 2016-10-27 | Umedica Laboratories Pvt. Ltd | Novel injectable composition of diclofenac sodium |
| CN107303266B (zh) * | 2016-04-18 | 2020-09-08 | 重庆润泽医药有限公司 | 左旋奥拉西坦注射液及其制备方法 |
| CN107303264A (zh) * | 2016-04-18 | 2017-10-31 | 重庆润泽医药有限公司 | 无泡沫左旋奥拉西坦注射液及其制备方法 |
| FR3077984B1 (fr) * | 2018-02-16 | 2020-02-21 | Vetoquinol Sa | Composition multiusage de torasemide |
| CN109498852B (zh) * | 2018-12-29 | 2022-06-24 | 广州噢斯荣医药技术有限公司 | 治疗骨科疾病的生物降解材料及其应用 |
| CN111103381A (zh) * | 2019-12-25 | 2020-05-05 | 南京希麦迪医药科技有限公司 | 一种液质联用测定人血浆中尼美舒利浓度的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389681A (en) * | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
| IT1283252B1 (it) * | 1996-03-15 | 1998-04-16 | Pulitzer Italiana | Soluzioni di piroxicam iniettabili per via parenterale |
| IN187306B (no) * | 1998-01-12 | 2002-03-23 | Panacea Biotec Ltd | |
| MY137736A (en) * | 2001-04-03 | 2009-03-31 | Pharmacia Corp | Reconstitutable parenteral composition |
| AU2003249510A1 (en) * | 2002-08-12 | 2004-02-25 | Ranbaxy Laboratories Limited | A parenteral dosage form of selective cox-2 inhibitors |
-
2006
- 2006-05-25 RS RSP-2007/0461A patent/RS20070461A/sr unknown
- 2006-05-25 BR BRPI0611170-0A patent/BRPI0611170A2/pt not_active IP Right Cessation
- 2006-05-25 KR KR1020077030585A patent/KR20080016689A/ko not_active Ceased
- 2006-05-25 CA CA002609242A patent/CA2609242A1/en not_active Abandoned
- 2006-05-25 WO PCT/IN2006/000177 patent/WO2006126214A2/en not_active Ceased
- 2006-05-25 JP JP2008513009A patent/JP2008542260A/ja not_active Withdrawn
- 2006-05-25 ZA ZA200711068A patent/ZA200711068B/xx unknown
- 2006-05-25 MX MX2007014862A patent/MX2007014862A/es not_active Application Discontinuation
- 2006-05-25 EA EA200702646A patent/EA200702646A1/ru unknown
- 2006-05-25 AU AU2006250765A patent/AU2006250765A1/en not_active Abandoned
- 2006-05-25 EP EP06756263A patent/EP1895983A2/en not_active Withdrawn
- 2006-05-25 CN CNA2006800250937A patent/CN101217939A/zh active Pending
-
2007
- 2007-12-14 NO NO20076468A patent/NO20076468L/no not_active Application Discontinuation
- 2007-12-19 CR CR9616A patent/CR9616A/es not_active Application Discontinuation
- 2007-12-21 TN TNP2007000482A patent/TNSN07482A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN07482A1 (fr) | 2009-03-17 |
| KR20080016689A (ko) | 2008-02-21 |
| EA200702646A1 (ru) | 2008-06-30 |
| MX2007014862A (es) | 2008-02-21 |
| EP1895983A2 (en) | 2008-03-12 |
| ZA200711068B (en) | 2009-03-25 |
| WO2006126214A2 (en) | 2006-11-30 |
| AU2006250765A1 (en) | 2006-11-30 |
| JP2008542260A (ja) | 2008-11-27 |
| RS20070461A (sr) | 2008-11-28 |
| CN101217939A (zh) | 2008-07-09 |
| WO2006126214A3 (en) | 2007-06-07 |
| CA2609242A1 (en) | 2006-11-30 |
| BRPI0611170A2 (pt) | 2010-08-17 |
| CR9616A (es) | 2008-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076468L (no) | Injiserbare sammensetninger og fremgangsmate for fremstilling av slike sammensetninger | |
| CY1122336T1 (el) | Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις | |
| DK1742624T3 (da) | Dopamin-agonist-kombinationsterapi med sedativer til forbedring af søvnkvalitet | |
| CL2011000101A1 (es) | Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas. | |
| MX2009002893A (es) | Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap). | |
| DK1970059T3 (da) | Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser | |
| NO20060424L (no) | 5-heteroringbaserte P38 kinaseinhibitorer | |
| DK1505973T3 (da) | Kombinationer til behandling af multipelt myelom | |
| ECSP077421A (es) | Compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1 | |
| MX2010002278A (es) | Farmacos antivirales para el tratamiento de una infeccion por arenavirus. | |
| AR109590A2 (es) | Régimen posológico para inhibidores de comt | |
| NO20051726L (no) | Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser | |
| ATE456565T1 (de) | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren | |
| CL2008002294A1 (es) | Compuestos derivados de benzotiazol acetamida y sus sales farmaceuticamente aceptables; composicion farmaceutica de dichos compuestos; su uso para tratar enfermedades mediadas por pi3 quinasa incluyendo melanoma, carcinoma y otras condiciones derivadas del cancer. | |
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| BR112013026202A2 (pt) | composições e usos terapêuticos de inibidores quinase epsilon relacionado a ikk e quinase i de ligação a tank | |
| SV2009003283A (es) | Inhibidores de la actividad de la akt | |
| CY1116215T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης | |
| EA200802166A1 (ru) | Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью | |
| AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
| JOP20240235A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| ATE542800T1 (de) | Kinasehemmer und ihre anwendungsverfahren | |
| WO2007143557A3 (en) | Compounds and methods for treating mammalian gastrointestinal parasitic infections | |
| EA200901237A1 (ru) | Применение димирацетама при лечении хронической боли | |
| CL2008003027A1 (es) | Compuestos derivados de 5,6-diaril piridinas sustituidas en posiciones 2 y 3; compuestos intermediarios y su uso; composicion farmaceutica; y uso para tratar y/o prevenir trastornos psiaquiatricos, metabolicos, inflamatorios, para la prevencion del dolor, entre otras enfermedades. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |